Results 151 to 160 of about 2,835,177 (286)

Cardiomyocyte NOX4 regulates resident macrophage-mediated inflammation and diastolic dysfunction in stress cardiomyopathy. [PDF]

Redox Biol, 2023
Vendrov AE, Xiao H, Lozhkin A, Hayami T, Hu G, Brody MJ, Sadoshima J, Zhang YY, Runge MS, Madamanchi NR.   +9 more
europepmc   +1 more source

Cardiomyopathy

Cardiomyopathy includes a spectrum of conditions of various pathologies. The appropriate diagnostic tools should be used to achieve the diagnosis and plan the appropriate management.
Maged William (21133769)
core  

Atypical Stress Cardiomyopathy: A Case Report. [PDF]

Cureus, 2022
Tavakolian K, Odak M, Miller B, Mararenko A, Nightingale S, Douedi S, Patel SV.   +6 more
europepmc   +1 more source

Mortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score

ESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher, Kensuke Matsushita, Shinnosuke Kikuchi, Taraneh Tatarcheh, Benjamin Marchandot, Amandine Granier, Said Amissi, Antonin Trimaille, Laurence Jesel, Patrick Ohlmann, Kiyoshi Hibi, Valérie Schini‐Kerth, Olivier Morel   +12 more
wiley   +1 more source

Exercise stress cardiomyopathy-a case report. [PDF]

Eur Heart J Case Rep
Russell PL, Martin J, Dwan MJ, Holland DJ.   +3 more
europepmc   +1 more source

Neurogenic Stunned Myocardium as Part of Stress Cardiomyopathy. [PDF]

Maedica (Bucur), 2022
Gherasim L, Nistor R.
europepmc   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

WONOEP appraisal: Biomarkers and treatment strategies beyond the synapse

Epilepsia, EarlyView.
Abstract Epilepsy is a heterogeneous neurological disorder affecting more than 70 million people worldwide, posing significant challenges for clinicians due to its complex etiology, diverse manifestations, variable treatment responses, and the inability to predict seizures or disease onset reliably.
Mirte Scheper, Zining Liu, Aristea S. Galanopoulou, Gernot Hlauschek, Benjamin Sinclair, Wai Lam Leung, Stefanie Dedeurwaerdere, Elisabeth Doran, Solomon L. Moshé, David C. Henshall, Ozlem Akman, Pablo M. Casillas‐Espinosa   +11 more
wiley   +1 more source

Coronary Microvascular Dysfunction in Stress Cardiomyopathy: At the Heart of the Problem. [PDF]

Life (Basel)
Piccolboni G, Civieri G, Tona F.
europepmc   +1 more source

A Case of Postpartum Takotsubo (Stress) Cardiomyopathy. [PDF]

Case Rep Cardiol, 2022
Kandah F, Deol T, Dhruva P, Chandler Z, Musa T, Velarde G.   +5 more
europepmc   +1 more source